Bruton’s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib

por Aalipour, Amin, Advani, Ranjana H.
Publicado 2014

Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas

por Aalipour, Amin, Advani, Ranjana H.
Publicado en Br J Haematol (2013)

Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88(L265P) Mutation

por Lynch, Ryan C., Advani, Ranjana H.
Publicado en Case Rep Oncol (2017)

Risk-adapted therapy for advanced-stage Hodgkin lymphoma

por Spinner, Michael A., Advani, Ranjana H.
Publicado en Hematology Am Soc Hematol Educ Program (2018)

Current concepts and controversies in the management of early stage Hodgkin lymphoma

por Maeda, Lauren S., Lee, Mark, Advani, Ranjana H.
Publicado en Leuk Lymphoma (2011)

Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation

por Spinner, Michael A., Advani, Ranjana H., Hoppe, Richard T., Lowsky, Robert, Muffly, Lori S.
Publicado en Blood Adv (2018)

Stage I-IIA Non-Bulky Hodgkin Lymphoma. Is Further Distinction Based on Prognostic Factors Useful? The Stanford Experience

por Advani, Ranjana H., Hoppe, Richard T, Maeda, Lauren S., Baer, David M., Mason, Joseph, Rosenberg, Saul A, Horning, Sandra J
Publicado 2010

Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials

por Koontz, Michael Zach, Horning, Sandra J., Balise, Raymond, Greenberg, Peter L., Rosenberg, Saul A., Hoppe, Richard T., Advani, Ranjana H.
Publicado 2013

DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set

por Vrabac, Damir, Smit, Akshay, Rojansky, Rebecca, Natkunam, Yasodha, Advani, Ranjana H., Ng, Andrew Y., Fernandez-Pol, Sebastian, Rajpurkar, Pranav
Publicado en Sci Data (2021)

Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial

por Advani, Ranjana H., Hong, Fangxin, Horning, Sandra J., Kahl, Brad S., Manola, Judith, Swinnen, Lode J., Habermann, Thomas M., Ganjoo, Kristen
Publicado 2011

Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era

por Tao, Li, Clarke, Christina A., Rosenberg, Aaron S., Advani, Ranjana H., Jonas, Brian A., Flowers, Christopher R., Keegan, Theresa H.M.
Publicado en Br J Haematol (2017)

Effect of CD47 Blockade on Vascular Inflammation

por Jarr, Kai-Uwe, Nakamoto, Ryusuke, Doan, Brandon H., Kojima, Yoko, Weissman, Irving L., Advani, Ranjana H., Iagaru, Andrei, Leeper, Nicholas J.
Publicado en N Engl J Med (2021)

Bevacizumab and CHOP (A-CHOP) in Combination for Patients with Peripheral T-Cell or Natural Killer Cell Neoplasms: An Eastern Cooperative Group Study (E2404)

por Ganjoo, Kristen, Hong, Fangxin, Horning, Sandra J., Gascoyne, Randy D., Natkunam, Yasodha, Swinnen, Lode J., Habermann, Thomas M., Kahl, Brad S., Advani, Ranjana H.
Publicado 2013

A Phase II Trial of R-CHOP Followed by Radioimmunotherapy for Early Stage (Stages I/II) Diffuse Large B-Cell Non-Hodgkin Lymphoma: ECOG3402

por Witzig, Thomas E., Hong, Fangxin, Micallef, Ivana N., Gascoyne, Randy D., Dogan, Ahmet, Wagner, Henry, Kahl, Brad S., Advani, Ranjana H., Horning, Sandra J.
Publicado en Br J Haematol (2015)

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)

por Chang, Julie E., Li, Hailun, Smith, Mitchell R., Gascoyne, Randy D., Paietta, Elisabeth M., Yang, David T., Advani, Ranjana H., Horning, Sandra J., Kahl, Brad S.
Publicado 2014

Breast Imaging in Women Previously Irradiated for Hodgkin Lymphoma

por Horst, Kathleen C., Fero, Katherine E., Hancock, Steven L., Advani, Ranjana H., Ikeda, Debra M., Daniel, Bruce, Rosenberg, Saul A., Donaldson, Sarah S., Hoppe, Richard T.
Publicado 2016

Response-Adapted Therapy for Aggressive non-Hodgkin's Lymphomas based on early [18F] FDG-PET Scanning: ECOG-ACRIN Cancer Research Group Study (E3404)

por Swinnen, Lode J., Li, Hailun, Quon, Andrew, Gascoyne, Randy, Hong, Fangxin, Ranheim, Erik A., Habermann, Thomas M., Kahl, Brad S., Horning, Sandra J., Advani, Ranjana H.
Publicado en Br J Haematol (2015)

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin

por Horwitz, Steven M., Advani, Ranjana H., Bartlett, Nancy L., Jacobsen, Eric D., Sharman, Jeff P., O’Connor, Owen A., Siddiqi, Tanya, Kennedy, Dana A., Oki, Yasuhiro
Publicado en Blood (2014)

Mantle Cell Lymphoma Initial Therapy with Abbreviated R-CHOP Followed by (90)Yibritumomab tiuxetan: Ten year follow-up of the Phase 2 ECOG-ACRIN study E1499

por Smith, Mitchell R., Hong, Fangxin, Li, Hailun, Gordon, Leo I., Gascoyne, Randall D., Paietta, Elisabeth M., Advani, Ranjana H., Forero-Torres, Andres, Horning, Sandra J., Kahl, Brad S.
Publicado en Leukemia (2016)

Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F...

por Swinnen, Lode J., O’Neill, Anne, Imus, Philip H., Gujar, Sachin, Schiff, David, Kleinberg, Lawrence R., Advani, Ranjana H., Dunbar, Erin M., Moore, Dennis, Grossman, Stuart A.
Publicado en Oncotarget (2017)